相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review
Zhongxun Yu et al.
RHEUMATOLOGY (2021)
Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?
Andre Heinen et al.
RHEUMATOLOGY (2021)
Comparison of Lesional Juvenile Myositis and Lupus Skin Reveals Overlapping Yet Unique Disease Pathophysiology
Jessica L. Turnier et al.
ARTHRITIS & RHEUMATOLOGY (2021)
From Diagnosis to Prognosis: Revisiting the Meaning of Muscle ISG15 Overexpression in Juvenile Inflammatory Myopathies
Cyrielle Hou et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Myositis-specific autoantibodies as relevant adjusting variables in myositis research: comment on the article by Hou et al
Iago Pinal-Fernandez et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis
Yuchuan Ding et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Inhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology
Cyril Gitiaux et al.
RHEUMATOLOGY (2020)
Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases
Adriana A. de Jesus et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool For Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis
Judith Wienke et al.
ARTHRITIS & RHEUMATOLOGY (2020)
A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate
Betul Sozeri et al.
RHEUMATOLOGY (2020)
Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies
Hanna Kim et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis
Charalampia Papadopoulou et al.
BRAIN (2019)
Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation
Judith Wienke et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Interferon-Stimulated Genes: What Do They All Do?
John W. Schoggins
ANNUAL REVIEW OF VIROLOGY, VOL 6, 2019 (2019)
Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
Sara Sabbagh et al.
BRAIN (2019)
Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features
Gian Marco Moneta et al.
ARTHRITIS & RHEUMATOLOGY (2019)
The Interferon (IFN) Class of Cytokines and the IFN Regulatory Factor (IRF) Transcription Factor Family
Hideo Negishi et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
Myogenic Progenitor Cells Exhibit Type I Interferon-Driven Proangiogenic Properties and Molecular Signature During Juvenile Dermatomyositis
Cyril Gitiaux et al.
ARTHRITIS & RHEUMATOLOGY (2018)
JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis
Leandro Ladislau et al.
BRAIN (2018)
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Gina A. Montealegre Sanchez et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Development of a Validated Interferon Score Using NanoString Technology
Hanna Kim et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2018)
Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
Massimo Gadina et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2018)
Update on outcome assessment in myositis
Lisa G. Rider et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Risk factors and disease mechanisms in myositis
Frederick W. Miller et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Medications received by patients with juvenile dermatomyositis
Takayuki Kishi et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α
Christopher J. M. Piper et al.
FRONTIERS IN IMMUNOLOGY (2018)
A child with severe juvenile dermatomyositis treated with ruxolitinib
Florence A. Aeschlimann et al.
BRAIN (2018)
Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools
Judith Wienke et al.
FRONTIERS IN IMMUNOLOGY (2018)
Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort
Sarah L. Tansley et al.
JOURNAL OF AUTOIMMUNITY (2017)
Detection of interferon alpha protein reveals differential levels and cellular sources in disease
Mathieu P. Rodero et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Hypoxia triggers IFN-I production in muscle: Implications in dermatomyositis
Noemi De Luna et al.
SCIENTIFIC REPORTS (2017)
Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon in dermatomyositis
C. Huard et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes
L. G. Rider et al.
JOURNAL OF INTERNAL MEDICINE (2016)
Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus
Hanna Kim et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2016)
New perspectives on type I IFNs in cancer
Thomas F. Gajewski et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
Role of Toll-like receptors and retinoic acid inducible gene I in endogenous production of type I interferon in dermatomyositis
Ling Li et al.
JOURNAL OF NEUROIMMUNOLOGY (2015)
Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated
Beverley Almeida et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Increased Levels of Eotaxin and MCP-1 in Juvenile Dermatomyositis Median 16.8 Years after Disease Onset; Associations with Disease Activity, Duration and Organ Damage
Helga Sanner et al.
PLOS ONE (2014)
Correlation of CXCL10, Tumor Necrosis Factor Receptor Type II, and Galectin 9 With Disease Activity in Juvenile Dermatomyositis
F. Bellutti Enders et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Whole microvascular unit deletions in dermatomyositis
Cyril Gitiaux et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Changes in Novel Biomarkers of Disease Activity in Juvenile and Adult Dermatomyositis Are Sensitive Biomarkers of Disease Course
Ann M. Reed et al.
ARTHRITIS AND RHEUMATISM (2012)
Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases
David Wong et al.
PLOS ONE (2012)
Juvenile dermatomyositis: new insights and new treatment strategies
Neil Martin et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2012)
Human Blood CXCR5+CD4+ T Cells Are Counterparts of T Follicular Cells and Contain Specific Subsets that Differentially Support Antibody Secretion
Rimpei Morita et al.
IMMUNITY (2011)
Type I interferon pathway in adult and juvenile dermatomyositis
Emily C. Baechler et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Interferon-Stimulated Gene 15 (ISG15) Conjugates Proteins in Dermatomyositis Muscle with Perifascicular Atrophy
Mohammad Salaiegheh et al.
ANNALS OF NEUROLOGY (2010)
Lesional and Nonlesional Skin From Patients With Untreated Juvenile Dermatomyositis Displays Increased Numbers of Mast Cells and Mature Plasmacytoid Dendritic Cells
Sheela Shrestha et al.
ARTHRITIS AND RHEUMATISM (2010)
Interleukin-6 and Type I Interferon-Regulated Genes and Chemokines Mark Disease Activity in Dermatomyositis
Hatice Bilgic et al.
ARTHRITIS AND RHEUMATISM (2009)
Elevated Serum Interferon-α Activity in Juvenile Dermatomyositis Associations With Disease Activity at Diagnosis and After Thirty-Six Months of Therapy
Timothy B. Niewold et al.
ARTHRITIS AND RHEUMATISM (2009)
An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity
Emily C. Baechler et al.
MOLECULAR MEDICINE (2007)
MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: Association with muscle involvement
Kevin A. O'Connor et al.
CLINICAL IMMUNOLOGY (2006)
Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis
N Fall et al.
ARTHRITIS AND RHEUMATISM (2005)
Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis:: A novel model of pathogenesis
Z Tezak et al.
JOURNAL OF IMMUNOLOGY (2002)
Elevated serum levels of soluble interleukin-2 receptor in juvenile dermatomyositis
I Kobayashi et al.
PEDIATRICS INTERNATIONAL (2001)
分享论文
